Dr. Parks, currently Senior Vice President of Marketing & Sales for the DSM Pharmaceutical Products business group of Royal DSM N.V. (NYSE, Euronext: DSM KON), has been appointed President and Business Unit Director of DSM Pharmaceuticals, Inc, as of June 1, 2012. Laura will continue to report to Alexander R. Wessels, President and Chief Executive Officer of DSM Pharmaceutical Products, as a member of the Management Team.
Dr. Parks joined DSM in 2008 and has held numerous positions in the life sciences industry including pharmaceuticals and food & nutrition for over twenty years. Headquartered in Parsippany, NJ (USA), DSM Pharmaceutical Products has a broad manufacturing platform for mammalian cell-based and microbial-based biopharmaceuticals, R&D/formulation and proprietary technologies for biologics, active pharmaceutical ingredients and fermentation, covering early stage drug development, clinical trials and commercial production as well as finished dosage form manufacturing across nine sites in the USA, Europe and Australia.
The finished dosage business, DSM Pharmaceuticals, Inc., is based in Greenville, North Carolina, and employees over 880 at the site, which specializes in the manufacture of solid dosage medicines and biopharmaceuticals. DSM Pharmaceutical Products’ facilities have been approved by the FDA, similar agencies in Europe, the Middle East, Africa and Japan and many other regulatory agencies. DSM Pharmaceuticals, Inc. is licensed by the US Drug Enforcement Administration to manufacture scheduled drugs.
Prior to DSM, Laura was with World Financial Group, and Solae (a Division of DuPont), a public company of over 10,000 employees, as Vice President of Sales. Prior to this, Laura served as Regional Vice President, North America with Solae leading their $120 million-dollar food ingredients business unit. Laura holds a Ph.D. in Food Science from the University of Georgia and a B.S. from The Ohio State University.